FINANCIAL & PERFORMANCE REPORT 2020

Global Antibiotic
Research & Development
Partnership

GARDP

FINANCIAL & PERFORMANCE REPORT 2020

TABLE OF CONTENTS

ORGANIZATIONAL BACKGROUND

LEGAL STATUS

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP was created by the World Health Organization (WHO) and the Drugs for Neglected Diseases *initiative* (DND*i*) in 2016 to ensure that everyone who needs antibiotics receives effective and affordable treatment. We aim to develop five new treatments by 2025 to fight drug-resistant infections. GARDP is funded by the governments of Germany, Japan, Luxembourg, Monaco, Netherlands, South Africa, Switzerland, United Kingdom, as well as Médecins Sans Frontières and private foundations. GARDP is registered under the legal name GARDP Foundation.

After four years in operation, GARDP has formed numerous partnerships with industry, academia and research institutions in support of its clinical programmes to develop antibiotics for drug-resistant infections for children, newborns with sepsis (a bloodstream infection), and sexually transmitted infections. These collaborations span the drug development lifecycle and include screening chemical libraries for antibacterial activity, assessing the viability of potential antibiotic candidates, and the completion of three clinical trials. We also work with partners on a range of educational and knowledge sharing activities in antibiotic R&D, including REVIVE (www.revive.gardp.org). Of particular significance is the pivotal, phase III global clinical trial GARDP is sponsoring for a novel, first-in-class antibiotic to treat gonorrhoea which commenced in 2019. We have formed over 60 partnerships in 22 countries that span governments, the biomedical and pharmaceutical industries, research institutions, non-profits, and civil society and have already built a pipeline to tackle drug-resistant infections in our priority areas. In 2020, we launched a serious bacterial infections (SBI) programme targeting drug-resistant infections in hospitalized adults and children.

GARDP bridges the gap between innovation and access by focusing on developing candidates in late-stage clinical development. This requires identifying the barriers to access and finding innovative ways to overcome them. We are also exploring ways to ensure there is a viable market and sustainable supply of treatments in the long-term.

To tackle the silent pandemic of antibiotic resistance, GARDP has set the 5 BY 25 goal, which seeks to deliver five new treatments by 2025 to tackle drug-resistant infections that pose the greatest threat to health and economic security.

2020 KEY FINANCIAL PERFORMANCE INDICATORS

EXPENDITURE

STEADY GROWTH IN SPENDING, CONCENTRATED ON R&D

- Overall expenditure totalled 23.7M in 2020, an increase of 26% (+EUR 4.8M)[1] over EUR 18.9M in 2019.
- R&D expenditure totalled EUR 19.7M and spending on social mission equated to 89% of total expenditure.
- Total GARDP expenditure since the start of its incubation within DND*i* in 2016 totals EUR 59M.

Expenditure Growth 2016-2020

(In million EUR)



Ratio of social mission/non-social mission

(In %)



89% OF SPENDING DEDICATED TO THE SOCIAL MISSION

GARDP's ratio of social mission to non-social mission spending increased from 87% in 2019 to 89% in 2020.

[1] *2020 figures include one off payments for licence fees to Venatorx.*

R&D EXPENDITURE PER PROGRAMME

R&D expenditure grew by 27%, (+4.2M) mainly driven by the creation of a new programme, Serious Bacterial Infections, and the strengthening of the R&D structure with the consolidation of the medical and pharmacovigilance functions and reinforcement of the clinical team throughout the year and across programmes. 2020 also saw GARDP enter into a new collaboration and licence agreement with US-based Venatorx Pharmaceuticals.

SERIOUS BACTERIAL INFECTIONS (SBI)

Serious bacterial infections are a major cause of death in hospitals and healthcare settings. GARDP is working to develop new treatments for these serious bacterial infections, focusing on treatments for drug-resistant bacteria on the WHO priority pathogens list.

Key Achievements:

- Signed an agreement with Venatorx Pharmaceuticals to accelerate the development of and access to cefepime-taniborbactam, a new compound that could show activity against two of the three WHO priority pathogens: *Enterobacterales and Pseudomonas aeruginosa*.
- Agreed the synopsis for the CRP feasibility/observational study with Venatorx.
- Supporting a phase 3 Venatorx-sponsored trial to test the efficacy and safety of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTI). Almost 90% of countries have now re-opened for enrolment in the trial following a pause in patient recruitment due to the COVID-19 pandemic and are actively recruiting patients. This pivotal trial will pave the way for the initial new drug registration and eventual approval of cefepime-taniborbactam by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

GARDP will collaborate with Venatorx on additional clinical trials in adults with multidrug-resistant infections; and clinical development of cefepime-taniborbactam, which includes a phase 3 complicated urinary tract infection trial, which is already in progress; additional clinical trials in adults with multidrug-resistant infections; and clinical development activities and trials to enable cefepime-taniborbactam to be used for children, including newborns with serious bacterial infections. Enrolment for the cUTI study is aimed to be completed in 2021 and recruitment for the observational study will start in early 2022.

SEXUALLY TRANSMITTED INFECTIONS (STI)

GARDP's STI programme aims to help tackle the spread of STIs by initially developing a new treatment for gonorrhoea including infections resistant to current treatments, investigating combinations of antibiotics to treat STIs and supporting the development of public health pathways to ensure sustainable access to treatment. With a total of EUR 3.6 M spent in 2020, the STI programme represented 18% of R&D expenditure in 2020.

GARDP has partnered with Entasis Therapeutics to initiate a global phase 3 trial of zoliflodacin, a novel first-in-class oral antibiotic for the treatment of uncompli-

cated gonorrhoea. The clinical study is expected to enrol approximately 1000 adults with urogenital gonorrhoea from sites in the Netherlands, South Africa, Thailand and the United States.

Due to the COVID-19 pandemic, GARDP decided to pause all patient enrolment in the US (notifying ethics committees and the FDA) and site activations in all other countries in March, hence year on year spend was reduced in 2020.

Key Achievements:

- Completed activation of all 6 US sites in Q1 2020 before the outbreak of the COVID-19 pandemic in March.
- Developed a re-launch strategy in June, which was based on an ongoing evaluation of how to conduct the study safely while continuing to collect high-quality data.
- Reactivated trial sites in the US and began enrolling patients in the Netherlands in June.
- Signed a memorandum of understanding with the Foundation for Innovative New Diagnostics (FIND) and the World Health Organization (WHO) to explore joint initiatives, with an initial priority focus on STIs, that could improve sustainable access to antibiotics and protect them against the emergence of antimicrobial resistance.
- Initiated a consultation process with key experts around zoliflodacin to identify the evidence necessary to understand public health need, optimize clinical management and support optimal use. We expect to finish the process by end 2021.

CHILDREN'S ANTIBIOTICS - NEONATAL SEPSIS

Each year, millions of newborns are diagnosed with neonatal sepsis, a life-threatening bloodstream infection that is becoming more dangerous due to the growing threat of antibiotic resistance. GARDP's neonatal sepsis activities aim to develop new combinations of existing antibiotics that can be used to replace ampicillin and gentamicin, the current WHO standard of care, and provide an evidence base for the use of antibiotics, both old and new, in neonates with confirmed or suspected sepsis. With a total of EUR 5.7 M spent in 2020, the Children's Antibiotics - Neonatal Sepsis programme represented 29% of R&D expenditure in 2020.

Key Achievements:

- Completed enrolment of the neonatal observational study, one of the largest ever studies on the care of babies with sepsis. Preliminary analyses on the clinical cohort have been completed and presented at the study results meeting for investigators held in October with the first publications in preparation.
- Identified combinations of 3 existing antibiotics for a potential neonatal sepsis treatment regimen during our asset evaluation activities.
- Began designing and planning a strategic public health trial to identify a treatment that could be used in settings where the current WHO standard treatment for clinically diagnosed neonatal sepsis can no longer be used. The initial design concept of this empiric treatment trial has been presented to the GARDP Scientific Advisory Committee (SAC) in November and the protocol synopsis is planned to be drafted for SAC approval in April 2021.
- Finalised the Clinical Study Report (results to be published in 2021) on the pharmacokinetic clinical trial in Kenya assessing the safety and dosing of the antibiotic fosfomycin in newborns as part of

the evaluation as a candidate for the strategic public health trial slated to begin in 2022.

CHILDREN'S ANTIBIOTICS - PAEDIATRIC DEVELOPMENT

GARDP's paediatric development activities focus on antibiotics that are either in late-stage clinical development or have already been approved for use in adults. The aim is to accelerate development of these antibiotics for use against serious bacterial infections in children for which there are currently limited or no treatment options in both low- and middle-income countries and high-income settings. With a total of EUR 3.4M, this programme represented 17% of R&D expenditure in 2020.

Following the agreement signed between GARDP and Venatorx Pharmaceuticals (see 'Serious Bacterial Infections'), the second project is the paediatric development of cefepime-taniborbactam, which is currently undergoing a phase 3 trial for use in adults. GARDP will seek regulatory approval for the use of cefepime-taniborbactam in children and newborns.

Key Achievements:

- GARDP continued to evaluate the potential of a partnership to support a paediatric development programme for polymyxin B. This existing antibiotic shows activity against multidrug-resistant infections in adults, but there are currently limited data around its safe and effective use in children and newborns.
- With the support of GARDP, Venatorx has led the creation of paediatric development plans for cefepime-taniborbactam, which were agreed with the EMA and the FDA in 2020

We will initiate cefepime-taniborbactam's paediatric development programme including juvenile toxicity studies and planning for clinical trials outlined in the paediatric study plan (PSP) and paediatric investigation plan (PIP) this year, with a view to beginning the first paediatric clinical trial of cefepime-taniborbactam in 2022 (pending the outcome of the phase 3 trial in adults).

ADVANCING ANTIBIOTIC RESEARCH AND DEVELOPMENT[2]:

GARDP's Advancing Antibiotic Research and Development activities include Asset Evaluation and Development; Discovery and Exploratory Research; and Scientific Affairs, including REVIVE. With a total of EUR 2.8M spent in 2020, Advancing Antibiotic Research and Development represented 14% of R&D expenditure in 2020.

ASSET EVALUATION & DEVELOPMENT:

GARDP's Asset Evaluation & Development activities focus on the identification, review and evaluation of both recovered assets and new chemical entities in development as candidates for GARDP's clinical programmes.

Key Achievements:

- Evaluated 22 new assets in 2020, including completion of comprehensive evaluation for seven new assets with SBI potential.
- Carried out systematic reviews and meta-analyses of antibiotic combinations used on carbapenem-resistant pathogens.
- Began conducting non-clinical studies on an approved asset to determine its viability as a potential treatment for sexually transmitted infections.
- Evaluation in hollow fibre models of potential antibiotic combinations for use in the neonatal sepsis strategic public health trial.

With cefepime-taniborbactam active against two of WHO's three carbapenem-resistant priority pathogens, our current focus is on identifying compounds that complement the activity of cefepime-taniborbactam by having the potential to cover the third: carbapenem-resistant *Acinetobacter baumannii*.

DISCOVERY & EXPLORATORY RESEARCH:

GARDP's Discovery & Exploratory Research activities aim to screen libraries and recover potential molecules

[2] *Was previously called Antimicrobial Resistance Memory Recovery and Exploratory Programme*

which may address WHO priority pathogens, namely *Klebsiella pneumoniae* and *Acinetobacter baumannii*, and feed into GARDP's programmes to develop new treatments.

Key Achievements:

- Screened over 24,000 compounds as single point concentration or dose-response confirmation of activity from four libraries.
- Daiichi Sankyo joined the Antimicrobial Resistance (AMR) Screening Consortium led by GARDP and provided access to a chemical library from their proprietary collection for screening in GARDP-designed antibacterial assays performed by the Institut Pasteur Korea.
- Identified and prioritized three hit compounds from AMR Screening Consortium partners for further investigation in 2021.
- GARDP, together with DND*i*, performed computer analyses of over 700,000 compounds from 25 natural product and/or natural product-like compound libraries. This analysis will inform the selection of library(ies) with high percentage of novelty and/or diversity for screening against *Klebsiella* and/or *Acinetobacter*.

SCIENTIFIC AFFAIRS :

GARDP's Scientific Affairs activities help to advance the development of new antimicrobial treatments by capturing and sharing the knowledge and skills of experts and making it freely accessible by all. GARDP's Scientific Affairs education and outreach activities aim to promote existing knowledge and expertise and share new discoveries and tools with the antibiotic R&D community, mainly through the online platform REVIVE.

The REVIVE website hosts our training, education, and outreach activities. It facilitates exchanges between clinical and non-clinical researchers with world-class experts active in antimicrobial R&D over the last 40 years. So far, more than 100 experts have engaged with REVIVE. This is helping to improve, accelerate, and streamline antimicrobial drug discovery, research, and development.

Key Achievements:

- Organized and broadcast 17 webinars to over 3,800 people from more than 100 countries.
- Collaborated with external organizations to develop sessions at key conferences including the fourth annual BIOCOM AMR Conference, where GARDP co-organized the session 'Top 10 mistakes in antibacterial development'.





- Co-developed two 'Bootcamps' for the American Society for Microbiology (ASM) and European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance (delivered as webinars due to COVID-19).
- REVIVE published 17 new Antimicrobial Viewpoints written by international experts in economics, antimicrobial stewardship and drug development.
- Launched a new Antimicrobial Encyclopaedia to provide definitions of key terms in the field, featuring eight videos from external contributors and GARDP experts.
- Developed and launched a Resource Library to host all REVIVE content in a single location and provide links to valuable external resources relevant to antimicrobial R&D.

R&D expenses per programme
(In million EUR)



R&D expenses per programme
(In %)



Children's Antibiotics - Neonatal Sepsis
Children's Antibiotics - Paediatric Development
Sexually Transmitted Infections
Advancing Antibiotic R&D*
Serious Bacterial Infections

** - Previously called Antimicrobial Memory Recovery and Exploratory/Discovery & Exploratory in 2019 report*

GARDP PIPELINE

GARDP's research and development work is focused on developing urgently needed treatments for infections caused by drug-resistant bacteria on WHO's priority pathogens list, and for populations disproportionately impacted by antibiotic resistance, including babies, children, the elderly, and hospitalized people.

GARDP is a not-for-profit organization focused on clinical development and access to antibiotics to treat drug-resistant infections.

GARDP's research and development pipeline outlines our activities and treatment candidates for each of our programmes areas, from discovery and clinical development to registration, access and stewardship.



GARDP manages research and development expenditures across the entire portfolio in accordance with strategic priorities. Decisions about whether or not to proceed with development projects is made on a project-by-project basis. These decisions are based on the project's potential to meet a significant unmet medical need or to improve patient outcomes, the strength of the science underlying the project, and the potential of the project (subject to the risks inherent in pharmaceutical development) to address patients unmet needs. Once a management decision has been made to proceed with the development of a particular molecule, the level of research and development investment required will be driven by many factors. These include the medical indications for which it is being developed, the number of indications being pursued, whether the molecule is of a chemical or biological nature, the stage of development, and the level of evidence necessary to demonstrate clinical efficacy and safety.

At each step of a product development, there is a substantial risk that a compound will not meet the requirements to progress further. In such an event, GARDP may be required to abandon the development of a compound in which substantial investment has already been made.

2020 KEY FINANCIAL PERFORMANCE INDICATORS

GLOBAL PERSONNEL COSTS

GARDP's personnel costs are largely made up of R&D employees and consultants who work directly within the R&D programmes both in countries where R&D activities take place, as well as in Switzerland. The GARDP model is to maximise synergies between its external partners and its in-house expertise to ensure the right balance of flexibility, scrutiny and knowledge across all programmes, as is required by a small and agile not-for-profit organization. Due to the therapeutic areas, territories, and size of the trials that GARDP conducts, together with the main drivers of clinical activity costs (clinical procedure and drug costs, site monitoring costs, staff costs), GARDP's organizational model entails a substantial use of human capital as reported through the level of FTE within our R&D programmes. This ensures projects are securely directed towards GARDP's public health and R&D objectives.



COUNTRY FTE
Switzerland 36
South Africa 6
United Kingdom 3
Thailand 2
United States 2
Australia 1
Germany 1
India 1
Kenya 1
Spain 1

GARDP FOOTPRINT IN 2020

Significant expertise was added in 2020 across the R&D programmes (Medical Director and Drugs Safety & Pharmacovigiliance lead) and within the support teams including Human Resources, Finance, and External Affairs. Total staff costs increased by 12% from EUR 6.7M in 2019 to EUR 7.5M in 2020 (+ EUR 0.8).

GARDP, through DND*i*, has a global presence with offices in several regions, including Africa, North America, Latin America and South Asia, and country

offices in Japan and India. In-country implementation of GARDP's programmes is supported by these offices and a joint DND*i*-GARDP office in Southern Africa. GARDP also has representation in Australia.

By the end of 2020, GARDP employed a total of 65 (54FTE) employees worldwide. The breakdown of resources, based on headcount between HQ and regional offices is 65%:35% vs 2019 (84%:16%). The figures include consultants specifically appointed to support its R&D activities. Overall there are 15 consultants working across the various functions, including R&D, Business Development, Communications and Access.

FTE by activity
(2019 and 2020)



GARDP - FULL TIME EQUIVALENT TREND

- 80% of staff are focused on Social Mission activities (R&D, Business Development, Policy & Advocacy and Communications as well as our global network undertaking these activities) in 2020. The percentages have remained stable when compared to 2019.
- GARDP is committed to developing its staff, attracting required expertise as well as closely managing its growth in fixed costs, especially in the current environment. Where possible, permanent staff are recruited in country or short-term support is hired as necessary for specific projects.

GENDER BALANCE GARDP

GARDP is committed to transparency regarding equality and diversity in all our activities including achieving gender balance across all areas within our organization. Consequently, GARDP will monitor its progress in this area year on year.

Gender equity among the GARDP team has remained relatively stable in 2020 compared to 2019.[3]

GARDP Gender Balance



[3] *Governance includes the Board of Directors, Audit Committee, Nominations, Remuneration & Safeguarding Committee, Strategy Partnerships Committee, Scientific Advisory Committee and the Donor Partnership Advisory Committee. For details see section 4.1 Governance.*

2020 KEY FINANCIAL PERFORMANCE INDICATORS

FUNDING

2020 FUNDING (TOTAL EUR 24M)

Income has grown by 27% between 2019 and 2020.

It is important that GARDP grows and diversifies its funder base. Alongside its objective to generate new sources of income in order to fund its mission, GARDP seeks flexibility in its funding support. This is key to both the management and development of a balanced portfolio. A year-on-year comparison of GARDP's funders is shown below.

2020 Funders



2019 Funders



COMMITMENTS AND PLEDGES TO DATE

Renewed funding shows growing commitment to GARDP's mission.[4]

PUBLIC CONTRIBUTORS 2016 - 2024	EUR
Germany (BMBF and BMG)	60.1 M
UK (DHSC - GAMRIF and NIHR)	15.9 M
The Netherlands (VWS)	7.5 M
Japan (Ministry of Health, Labour and Welfare)	1.5 M
Switzerland (FOPH)	1.2 M
South African Medical Research Council	0.6 M
Principality of Monaco	0.4 M
Grand Duchy of Luxemburg	0.1 M

PRIVATE CONTRIBUTORS 2016 - 2024	EUR
Bill & Melinda Gates Foundation	1.8 M
Wellcome Trust	1.1 M
Others (Médecins Sans Frontières, Leo Model Foundation)	0.7 M

Germany's (BMBF) and the UK's Department of Health and Social Care (GAMRIF) increased their financial support to GARDP in 2020 by contributing a further EUR 5M and £2.5M respectively. The Leo Model Foundation also extended its support to GARDP with an additional $ 50,000.

New funding of $1.8M (April 20 – March 21) was received from the Japanese Ministry of Health, Labour and Welfare (with a pledge for a further $7.2M over the next four years).

By the end of the year, GARDP had secured a total of EUR 97 million in commitments (91M) and pledges (6M).

69% PORTFOLIO FUNDING

GARDP receives funding with varying levels of flexibility. Funds committed at the level of the portfolio allow GARDP to respond quickly to research opportunities within a broad portfolio of projects. Balanced and flexible funding allows GARDP to effectively manage its priorities at both programmatic and portfolio levels.



[4] *Tables showing public and private contributions include only committed funding.*

COMBINED FINANCIAL STATEMENTS

The management is responsible for the preparation of the combined financial statements and related information that is presented in this report. The combined financial statements include amounts based on estimates and judgments made by the Finance department.

Following a competitive audit tender, Deloitte SA was reappointed as the independent auditor by the GARDP Foundation upon the recommendation of the Audit Committee to audit and opine on the combined financial statements of the GARDP Foundation.

The GARDP Board, through its Audit Committee, meets periodically with the Finance department and the statutory auditor to ensure that each is meeting its responsibilities, and to discuss matters concerning internal controls and financial reporting.

The Board of Directors and management of the Foundation are responsible for establishing and maintaining adequate internal control over financial reporting. The Foundation's internal control system is designed to provide reasonable assurance to the management and Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of its published combined financial statements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective may not prevent or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Foundation's management assessed the effectiveness of the foundation's internal control over financial reporting as of 31 December 2020. Based on our assessment, management concluded that, as of 31 December 2020, the Foundation's internal control over financial reporting is effective. Deloitte SA has tested the design and implementation of the Foundation's internal control over financial reporting, which is reflected in their audit opinion included in this annual report under "Section 4. Report of Statutory Auditor".

There were no changes to our internal control over financial reporting that occurred during the period covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

These combined financial statements for the year ending 31 December 2020 were approved by the Board of Directors on 6 July 2021.

BALANCE SHEET

AT 31 DECEMBER 2020 WITH 2019 COMPARATIVE FIGURES

(EXPRESSED IN EUR)	NOTES	2020	2019
CURRENT ASSETS:			
Cash and cash equivalents			
Cash and banks at headquarters		10'747'701	9'953'908
Cash and banks at regional and affiliate offices		9'554	47'765
Time deposits		3'695'400	4'403'635
Total cash and cash equivalents		**14'452'656**	**14'405'308**
Current accounts and receivables			
Advances to staff		6'031	5'899
Receivables from public institutional donors		677'138	677'051
Other receivables		149'769	26'885
Prepaid expenses		117'928	557'594
Total current accounts & receivables		**950'865**	**1'267'429**
TOTAL CURRENT ASSETS		**15'403'521**	**15'672'737**
NON CURRENT ASSETS:			
Intangible assets	2	144'906	117'868
Bank guarantee deposits		0	634
Total non-current assets		**144'906**	**118'502**
TOTAL		**15'548'427**	**15'791'239**
CURRENT LIABILITIES:			
Payables		**1'585'865**	**4'000'313**
Accrued expenses		**158'915**	**629'335**
Deferred income	**4**	**13'597'503**	**10'942'841**
Provisions	**3**	**153'974**	**174'473**
Total current liabilities		**15'496'258**	**15'746'962**
CAPITAL OF THE ORGANISATION:			
Paid-in capital		44'275	44'275
Result for the year		7'892	2
Restricted operating funds		0	0
Unrestricted operating funds		2	0
Total capital of the organization		**52'169**	**44'277**
TOTAL		**15'548'427**	**15'791'239**

COMBINED STATEMENT OF OPERATIONS

2020 WITH 2019 COMPARATIVE FIGURES

(EXPRESSED IN EUR)	NOTES	2020	2019
INCOME			
Public institutional funding:			
Govern. & public int. organiz. unrestricted		2'870'212	874'050
Govern. & public int. organiz. restricted		20'569'918	16'528'218
Total public institutional funding		**23'440'130**	**17'402'268**
Private resources:			
Private foundations, corp. and individuals, unrestricted		2'872	44'500
Private foundations, corp. and individuals, restricted		490'156	1'471'332
Total private resources:		493'027	1'515'832
Other income:			
Sundry income & reimbursements		75'239	6'412
Other income net		**75'239**	**6'412**
TOTAL INCOME	**4 / 5**	**24'008'397**	**18'924'512**
SOCIAL MISSION EXPENDITURE			
Research & development expenditure:			
Research & development coordination and supervision		3'486'875	4'250'544
Children's Antibiotics - Neonatal Sepsis		5'682'538	2'801'705
Children's Antibiotics - Paediatric Development		3'440'195	640'190
Sexually Transmitted Infections		3'563'221	6'510'041
Serious Bacterial Infections		703'143	-
Advancing Antibiotic Research and Development		2'801'504	1'236'462
Total research & development expenditure		**19'677'476**	**15'438'942**
International network expenditure		1'394'813	1'049'697
TOTAL SOCIAL MISSION EXPENDITURE		**21'072'289**	**16'488'639**
NON-SOCIAL MISSION EXPENDITURE			
Fundraising & General Administration		2'642'344	2'386'869
Total non-social mission expenditure		**2'642'344**	**2'386'869**
TOTAL EXPENDITURE	**6**	**23'714'634**	**18'875'508**
Operating surplus / (loss)		293'763	49'004
OTHER INCOME (EXPENSES)			
Financial income, net		7'893	572
Exchange gain (loss), net		(293'764)	(49'574)
TOTAL OTHER INCOME (EXPENSES)		**(285'871)**	**(49'002)**
Net surplus for the year prior to allocations		7'892	2
Release from restricted operating funds			-
Allocation to unrestricted operating funds		(7'892)	(2)
NET SURPLUS FOR THE YEAR AFTER ALLOCATIONS			

CASH FLOW STATEMENT

FOR THE 12MONTH PERIOD ENDED 31 DECEMBER 2020

(EXPRESSED IN EUR)	2020	2019
INCOME		
Net surplus (loss) for the year, unrestricted	**7'892**	**2**
Depreciation of intangible assets	69'520	28'451
Increase (decrease) in provisions	(20'499)	174'473
(Increase) decrease in advances	(132)	(5'899)
(Increase) decrease in receivables from donors	(86)	(677'051)
(Increase) decrease in founding partner and other receivab	(122'884)	(26'885)
Increase (decrease) in prepaid expenses	439'666	(557'594)
Increase (decrease) in payables	(2'414'448)	4'000'313
Increase (decrease) in accrued expenses	(470'419)	629'335
Increase (decrease) in deferred income	2'654'662	10'942'841
FUNDS FLOW FORM OPERATING ACTIVITIES	**143'272**	**14'507'986**
(Aquisition) disposal of intangible assets	(96'558)	(146'319)
(Increase) decrease in bank guarantee deposits	634	(634)
FUNDS FLOW FORM OPERATING ACTIVITIES	**(95'924)**	**(146,953)**
Inflow from captial paid in	-	44'275
FUNDS FLOW FORM FINANCIHNG ACTIVITIES	**-**	**44'275**
NET CHANGE IN CASH	**47'348**	**14'405'308**
Cash at the beginning of the year	**14'405'308**	**-**
Net Change in Cash	47'348	14'405'308
Cash at the beginning of the year	**14'452'656**	**14'405'308**

STATEMENT OF CHANGES IN CAPITAL

AS AT 31 DECEMBER 2020	OPENING BALANCE	ALLOCATION	INTERNAL FUND TRANSFERS	CLOSING BALANCE
Paid-in capital	44,275	-	-	44'275
Surplus (loss) for the year		7'892	(7892)	-
Restricted operating funds				-
Unrestricted operating funds	2	-	7'892	7'894
Capital of the organization	**44,277**	**7'892**	**-**	**52'169**
AS AT 31 DECEMBER 2019	**OPENING BALANCE**	**ALLOCATION**	**INTERNAL FUND TRANSFERS**	**CLOSING BALANCE**
Paid-in captial	44,275	-	-	44'275
Surplus (loss) for the year		2	(2)	-
Restricted operating funds				-
Unrestricted operating funds	-	-	2	2
Capital of the organization	**44,275**	**2**	**-**	**44'277**

1. EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

The accompanying notes are an integral part of this combined financial statement.

1. GENERAL INFORMATION

As the GARDP Foundation was incorporated in July 2018 and received material grants directly, activities of GARDP took place both in the DND*i* and GARDP legal entities in 2018. GARDP became an autonomous legal entity on 1 April 2019. GARDP entered into a Transfer Agreement with DND*i* under which all employees, assets and activities were transferred to GARDP effective 1 April 2019. Consequently, GARDP activities were progressively transferred from DND*i* to the new GARDP Foundation, including R&D contracts which were all transferred to GARDP by the end of 2019.

The purpose of these financial statements is to represent the combined activities of GARDP in 2020 for the year ending 31 December 2020 compared to the year ending 31 December 2019. This is in order to show our donors a true and accurate picture of all GARDP activities both within GARDP and DND*i* (prior to the transfer on 1 April 2019).

In 2020, a novel coronavirus brought suffering, disruption and economic hardship to virtually every corner of the globe. GARDP quickly developed business continuity plans across the organization to be adjusted as necessary during the COVID-19 pandemic and specifically an impact assessment of COVID-19 on its R&D programmes with a priority focus on clinical trials. GARDP made decisions to pause recruitment and delay the start of some clinical trials based on key criteria including site staff and patient safety. The far-reaching implications of this pandemic are not yet understood as the pandemic keeps developing across the globe in 2021, however GARDP will keep monitoring the situation in constant dialogue with our partners and donors, update its business continuity plans as necessary, and continuously assess the impact of COVID-19 on our staff, patients, partners, sites with particular reference to our clinical studies.

A. Legal aspects

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss Foundation registered in Geneva under statutes dated 21 June 2018 as a not-for-profit legal entity, with headquarters in Geneva. GARDP is monitored by the Swiss Federal Supervisory Board for Foundations and has applied for and been granted "Other International Organization" status as of 10 March 2021.

The purpose of GARDP, as per its Charter, is "to develop new health technologies to tackle global and regional public health priorities where there are research and development or access gaps, contributing in particular to the fight against antimicrobial resistance and diseases that affect vulnerable populations,

and fostering appropriate use and enhancing access to such technologies".

Per its charter, "GARDP may pursue all such activities as may be appropriate to attain its purpose, including raising funds for the purpose of the Foundation. GARDP may inter alia engage in:

- Conducting, supporting and stimulating the research and development of new health technologies, including medicines, vaccines and diagnostic tools as well as other technologies;
- Fostering appropriate use and equitable access to such health technologies;
- Raising awareness on the need to invest in research and development in health technologies, appropriate use and equitable access to health technologies; and
- Supporting other relevant global and regional initiatives in public health.
- GARDP will primarily focus on health technologies for humans but may also engage in the research and development of health technologies for animals and plants where this can contribute to protect human health".

B. Income tax

An application with the Swiss Federal Council for "Other International Organization" status was filed with the Swiss Confederation in December 2018. The purpose of this application is to grant GARDP certain privileges, including:

- Exoneration from all direct and indirect federal, cantonal and communal taxes;
- Exoneration from all indirect taxes (VAT) on all goods and services acquired for the sole use of the foundation within Switzerland; and
- Unrestricted access to work permits for non-Swiss, non-EU nationals.

This application was granted on 10 March 2021. As a result of this privileged status granted by the Swiss government, GARDP is now VAT exempt in Switzerland and can employ foreign employees (EU or non-EU citizens alike) without any Swiss immigration law restrictions.

C. International Network

GARDP, through DND*i*, has a global presence with offices in several countries, including Africa, North America, Latin America and South Asia. As outlined in the Subsequent Events paragraph of our 2018 report, the GARDP Foundation entered into a collaboration agreement with DND*i* effective 1 January 2019. Under this collaboration agreement, the GARDP Foundation is able to use the local infrastructure provided by DND*i* to GARDP until 21 December 2021. Through this network, GARDP has the ability to develop R&D activities with local partners (clinical trials, observational studies, etc.), but also develop relationships with local governments or funders.

In June 2018, GARDP also registered a non-profit company in Cape Town, South Africa, with DND*i*. This non-profit company ("DND*i* GARDP Southern Africa NPC") is a joint company with DND*i* and allows GARDP to develop local GARDP activities.

2. SIGNIFICANT ACCOUNTING POLICIES

A. Accounting basis

The financial statements of the Foundation have been prepared in accordance with the provisions of the Swiss Code of Obligations. They have been prepared under the requirements of the Swiss GAAP FER, in particular Swiss GAAP FER 21 relating to accounting for charitable non-profit organizations.

B. Scope of the financial statement

This report presents the combined GARDP activities included in the GARDP Foundation in 2020 and those activities that were undertaken on behalf of GARDP by DND*i*, including the activities of the legal entity DND*i* GARDP South Africa NPC, which has been working on GARDP projects since 1 July 2019. The report presents the combined statement of operations of GARDP, balance sheet, cash flow statement and statement of changes in capital statement for 2019 and 2020 as well as notes to the accounts.

C. Basis of consolidation

The combined accounts include the GARDP legal entity in Switzerland and GARDP activity undertaken by the separate legal entity in South Africa "DND*i* GARDP Southern Africa NPC".

D. Social mission expenditure

Social mission expenditure encompasses expenses that support GARDP's mission to develop new treatments for drug-resistant infections that pose the greatest threat to health and ensure that everyone who needs antibiotics receives effective and affordable treatment. This includes work carried out by the research & development, policy & advocacy, communications, and business development/access teams as well as our global network undertaking these activities. GARDP's non-social mission expenditure comprises our fundraising, IT, finance and human resources activities.

E. Functional currency

The GARDP Board has determined that the assets, liabilities, and operations should be measured using EUR as the functional currency. The environment in which the entity primarily generates and expends cash determines this decision. All amounts presented in the financial statement are stated in EUR, except when specified otherwise.

F. Foreign currency translation

Transactions in currencies other than functional currency (EUR) are converted at the monthly average of the daily closing exchange rate of the previous month. Year-end balances in other currencies are converted at the last prevailing exchange rates available in the system for the year. Resulting exchange gains or losses are recognized in the Statement of Operations.

The principal exchange rates used at the year-end to re-evaluate the balance sheet items in EUR, including our cash balances, are:

CURRENCY	2020	2019
USD/EUR	0.8451	0.9051
CHF/EUR	0.9278	0.9113
GBP/EUR	1.1163	1.1660
ZAR/EUR	0.0544	0.0612

G. Income and deferred income

Restricted public and private contributions based on annual or multi-year agreements are recorded, over the life of the agreement, as and when the milestones set out in the agreement are achieved.

Unrestricted public and private contributions based on annual or multi-year agreements are recorded on an accrual basis over the life of the agreement.

A reconciliation between contributions committed to GARDP and income recognized in the statement of operations is shown under section 4 below.

Other small (below equivalent to EUR 50'000) contributions are recorded on a cash basis.

H. Expenditures incurred for projects and activities

All expenditure is on an accruals basis.

R&D vendors expenditure are recorded as follows:

- Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&D, whether they are deemed to transfer intellectual property to GARDP or not, are expensed as R&D expenses in the period in which they are incurred.
- Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are also expensed, as are payments for other assets, such as technologies to be used in R&D activities.
- Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as access expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are also expensed as incurred.

Partners' expenditures are recorded as follows:

- If financial reports are unavailable by the deadline of 1 March of the following year, the amount is calculated on an estimate basis provided by the partner. The unpaid portion remaining at year-end is included under current liabilities.

I. Credit risk, liquidity risk and cash flow management

GARDP has built relationships with private sector banks to manage its financial assets and provide appropriate liquidity and risk management. GARDP's liquid assets are maintained in cash, low-risk, short-term deposits or capital-guaranteed investments. Any form of speculation is prohibited.

At the balance sheet date, GARDP had cash freely available of EUR 10.8M (2019 10M) and short-term deposits of EUR 3.7M (2019 4.4M), making a total of EUR 14.5M (2019 14.4M). There was no significant concentration of credit risk.

The main financial risk for GARDP is the volatility of foreign exchange rates that can affect the value of its holding in various currencies (USD, EUR, GBP, CHF and ZAR). GARDP is exposed to currency risk on contributions received, project expenditures, and general and administrative expenses that are denominated in a currency other than the functional currency (EUR). These transactions are mainly denominated in EUR, CHF, USD, GBP and ZAR.

GARDP ensures that its net exposure is kept to an acceptable level by buying or selling foreign currencies at spot rates when necessary, to address short-term imbalances. The diversity of funding currencies represents a partial natural hedging mechanism (income in CHF, EUR, GBP, USD and ZAR).

J. Tangible and Intangible fixed assets

Tangible and intangible fixed assets are stated at cost in EUR, less accumulated depreciation. Depreciation is charged to the Statement of Operations on a straight-line basis over the estimated useful lives of the assets.

The rates of depreciation used are based on the following estimated useful lives:

Tangible	
Office fittings and equipment	**20%**
IT equipment	**33%**
Intangible	
Computer software	**33%**

K. Provisions

A provision is recognized on the balance sheet when the organization has a legal or constructive obligation resulting from a past event, and it is probable that a payment will be required to settle the obligation. Provisions are measured at the management's best estimates of the expenditure required to settle that obligation at the balance sheet date.

L. Organizational capital

The founding capital of CHF 50,000 referenced in the statutes was received from the founding members of GARDP, DND*i* and WHO. The capital is fully paid in.

M. Restricted and unrestricted reserves

Restricted and unrestricted reserves represent the excess of income over expenditure since the inception of GARDP. The revenue recognition policy of allocating unmatched revenue to the deferred income balance on the balance sheet at year end means that restricted reserves are not created in the normal course of business.

N. In-kind donations

Gifts in kind are not recorded but disclosed in the notes to the financial statement and valued at fair market values according to the following principles: in-kind goods transferred to a GARDP project or services rendered to GARDP must be free, excluding the involvement of a monetary transfer. They must be:

- Clearly identifiable and part of GARDP's projects and activities, as defined by GARDP's action plans and budgets.
- Recognizable as a visible contribution to GARDP's projects and activities, and in line with GARDP's mission and objectives.

For goods or services paid at prices below market prices, the difference between real payment and current market price is not considered as a gift in kind.

Fair market value is defined as the price GARDP would have paid to utilize the goods or service. Fair market value can be suggested by partners. However, GARDP is careful not to overestimate in accordance with the prudence principle.

Gifts in kind estimated at EUR 5,000 and above are taken into account. Exceptions can be made by GARDP when it serves the purpose of providing consistency and completeness of a project's accounts.

2. INTANGIBLE ASSETS

CURRENT YEAR (EXPRESSED IN EUR)	COMPUTER SOFTWARE	TOTAL
ACQUISITION COST		
Balance as of 01.01.2020	146'319	146'319
Additions	96'558	96'558
Disposals	-	-
End of the period 31.12.2020	242'877	242'877
ACCUMULATED AMORTIZATION		
Balance as of 01.01.2020	28'451	28'451
Charge for the year	69'520	69'520
Disposals	-	-
Impairment	-	-
End of the period 31.12.2020	97'971	97'971
Net Book Value as of 31.12.2020	144'906	144'906

PRIOR PERIOD (EXPRESSED IN EUR)	COMPUTER SOFTWARE	TOTAL
ACQUISITION COST		
Balance as of 01.01.2019	-	-
Additions	146'319	146'319
Disposals	-	-
End of the period 31.12.2019	146'319	146'319
ACCUMULATED AMORTIZATION		
Balance as of 01.01.2019	-	-
Charge for the year	28'451	28'451
Disposals	-	-
Impairment	-	-
End of the period 31.12.2019	28'451	28'451
Net Book Value as of 31.12.2019	117'868	117'868

As at 31 December 2020 GARDP had Intangible assets relating to the third party charges for setup of various information systems (CRM, Sharepoint, Contract Management software). No internal IT costs have been capitalized and hardware items purchased for less than EUR 5,000 are expensed when acquired..

3. PROVISIONS

The year-on-year increase reflects an increase in staff holiday not taken, primarily driven by the restrictions on travel caused by COVID-19. The general provision relates to a liability for Acquisition VAT. GARDP has been evaluating the liability in 2020 and feels comfortable to reduce the level based on the latest expected outcome.

2020	PROVISION FOR HR EXPENSES (HOLIDAYS NOT TAKEN AND OTHER HR)	PROVISION FOR GENERAL RISK	TOTAL
Carrying balance as at 31.12.2019	**54,473**	**120,000**	**174,473**
Creation	103,974	-	**103,974**
Utilization	-54,473	-	**-54,473**
Reversal	-	-70,000	**-70,000**
Carrying balance as at 31.12.2020	**103,974**	**50,000**	**153,974**

2019	PROVISION FOR HR EXPENSES (HOLIDAYS NOT TAKEN AND OTHER HR)	PROVISION FOR GENERAL RISK	TOTAL
Carrying balance as at 31.12.2018	**-**	**-**	**-**
Creation	54,473	120,000	**174,473**
Carrying balance as at 31.12.2019	**54,473**	**120,000**	**174,473**

4. INCOME AND DEFERRED INCOME

RECEIVABLE FROM FUNDERS VERSUS DEFERRED INCOME

Total deferred income remains at a high level in 2020 (EUR 13,597,503) compared to 2019 (EUR 10,942,841). The increase is due to delays in R&D expenditure mainly resulting from the impact of the COVID-19 pandemic. There are funder receivables of EUR 677,138 as of 31 December 2020 (2019 EUR 677,051).

CUMULATIVE COMMITMENTS TO GARDP AND/OR RECEIVED BY 2020

The list of cumulative funding committed to and /or received by GARDP as of 2020 is as follows:

FUNDERS	CURRENCY	TYPE	TOTAL COMMITMENT in Currency	TOTAL COMMITMENT in EUR	AS PER THE STATEMENT OF OPERATIONS 2020 in EUR	TOTAL SPENT TO DATE in EUR	TO BE USED AFTER 2020 in EUR
Bill & Melinda Gates Foundation	USD	Restricted	1'990'889	1'758'585	447'110	1'758'585	-
Wellcome Trust	EUR	Portfolio	1'083'800	1'083'800	-	1'083'800	-
Médecins Sans Frontières	EUR	Unrestricted	600'000	600'000	-	600'000	-
Leo Model Foundation	USD	Unrestricted	150'000	129'894	43'046	129'894	-
UK (DFID)	GBP	Unrestricted	3'075'047	3'494'922	-	3'494'922	
Germany (BMBF)	EUR	Portfolio	55'000'000	55'000'000	13'947'163	30'988'461	24'011'539
Germany (BMG)	EUR	Portfolio	5'100'000	5'100'000	467'118	4'567'118	532'882
The Netherlands (VWS)	EUR	Unrestricted	7'500'000	7'500'000	1'000'000	4'000'000	3'500'000
Switzerland (FOPH)	CHF	Portfolio	1'360'000	1'205'096	144'868	1'139'440	65'656
Luxembourg (Ministry of Health)	EUR	Unrestricted	115'000	115'000	15'000	115'000	-
South African Medical Research Council	ZAR	Portfolio	10'000'000	638'769	27'279	638'769	-
Principality of Monaco	EUR	Restricted	400'000	400'000	141'476	241'476	158'524
UK (DHSC - GAMRIF)	GBP	Unrestricted /Restricted	7'000'000	7'865'598	2'670'691	5'252'143	2'613'455
UK (DHSC - NIHR)	GBP	Restricted	4'000'000	4'598'214	3'864'777	4'050'717	547'497
Japan (Ministry of Health, Labour & Welfare)	USD	Unrestricted	1'802'000	1'541'521	1'231'757	1'231'757	309'764
Total Funding (EUR)			**-**	**91'031'399**	**24'000'286**	**59'292'082**	**31'739'317**

Notes for cumulative funding committed table [5]:

- Total commitment includes funding that was received by DNDi on behalf of GARDP during GARDP's incubation in DNDi. The total amount of funding has been shown here to provide the reader with the full details relating to GARDP since its inception in 2016.

- **Bill & Melinda Gates Foundation (BMGF):** restricted funding in support of the global neonatal observational study that is part of the Children's Antibiotics - Neonatal Sepsis programme covering May 2018 – May 2021. Focus on BMGF target countries. The grant was transferred from DNDi to GARDP at the end of October 2019.
- **Leo Model Foundation:** unrestricted funding covering 2018- 2020.
- **United Kingdom (Department of Health and Social Care (Global AMR Innovation Fund (GAMRIF) & National Institute for Health Research (NIHR)):** funding consisting of several contributions: restricted £1M grant from DHSC (Global AMR Innovation Fund (GAMRIF)) in support of the Sexually Transferred Infections programme for the period May 2018 – March 2019, a multi-year restricted grant of £5M funding from DHSC (GAMRIF) in support of the Sexually Transmitted Infections programme covering July 2019 – March 2022, a restricted £4M grant from the NIHR in support of the Children's Antibiotics - Neonatal Sepsis programme for the period October 2019 – March 2021 and an unrestricted £1m grant from DHSC (GAMRIF) covering April 2020 – March 2021.
- **Germany (BMBF):** portfolio funding consisting of four grants covering all the GARDP programmes from October 2018 – January 2023.
- **Germany (BMG):** funding consisting of several contributions: unrestricted funding of EUR 500,000 covering March 2016 – January 2017. Restricted funding of EUR 750,000 in support of the Children's Antibiotics - Neonatal Sepsis programme and Coordination covering February 2017 – December 2017. Restricted funding of EUR 1,350,000 in support of AMREP, Sexually Transmitted Infections programme and coordination covering August 2017 – February 2018. Restricted funding of EUR 1,000,000 in support of Sexually Transmitted Infections programme and Children's Antibiotics - Neonatal Sepsis programme covering August 2018 – February 2019. Restricted funding of EUR 500,000 in support of GARDP's migration to an independent legal entity covering December 2018 – February 2019. Restricted funding of EUR 1,000,000 in support of Sexually Transmitted Infections programme covering January 2020 – September 2021.
- **Netherlands (VWS):** funding consists of several contributions: unrestricted funding of EUR 500,000 covering July 2017 – January 2018 and unrestricted funding of EUR 2,000,000 covering January 2018 – December 2018. Unrestricted funding of EUR 5,000,000 covering 2019-2024 to support the delivery of 5 new treatments by 2025.
- **Switzerland (FOPH):** funding consists of several contributions: unrestricted seed funding of CHF 360,000 covering September 2016 – October 2017. Unrestricted funding of CHF 500,000 with part allocated to AMREP covering June 2017 – August 2019. Restricted funding of CHF 500,000 covering the period 2019 – 2021 for Asset Evaluation and Development and Scientific Affairs and REVIVE.
- **Grand Duchy of Luxembourg:** unrestricted funding covering up until end September 2018. The funds were spent in 2017. Unrestricted funding of EUR 15,000 covering 2020.
- **South Africa Medical Research Council (SAMRC):** funding consists of two contributions: restricted funding of ZAR 6,000,000 for R&D of new and/or improved treatments covering March 2017 – March 2020. Restricted funding of ZAR 4,000,000 in support of Children's Antibiotics - Neonatal Sepsis programme and Sexually Transmitted Infections programme activities in South Africa covering April 2018 – March 2019.
- **Principality of Monaco:** restricted funding of EUR 400,000 in support of Children's Antibiotics - Neonatal Sepsis programme activities in South Africa covering the period 2019 – 2021.
- **Japanese Ministry of Health, Labour and Welfare:** unrestricted funding of USD 1,802,000 covering April 2020 – March 2021. Further unrestricted funding of USD 7.2M has been pledged covering April 2021 – March 2025.

[5] *Income recognized in 2020 statement of operations does not include deferred income.*

5. FUNDING PER PROJECT (RESTRICTED AND UNRESTRICTED)

2020 Funding per project

	TOTAL EXPENDITURE	UK DHSC (Restricted/ Unrestricted)	THE NETHERLANDS (VWS) (Unrestricted)	GERMANY (BMG) (Restricted)	GERMANY (BMBF) (Restricted)	BILL & MELINDA GATES FOUNDATION (Restricted)	SWITTZERLAND FOPH (Restricted)	JAPAN (Unrestricted)	PRINCIPALITY OF MONACO (Restricted)	OTHER[1] (Restricted and Unrestricted)
Research & development coordination and supervision	3'486'875	647'836	593'488	76'856	1'970' 645	-	-	184'847	4'524	8'680
Children's Antibiotics - Neonatal Sepsis	5'682'538	1'860'166	413	-	3'317'327	356'078	-	33'481	108'616	6'457
Children's Antibiotics - Paediatrics Development	3'440'195	1'605'574	-	-	1'822'730	3'165	-	-	8'726	-
Sexually Transmitted Infections	3'563'221	1'541'490	5	316'606	1'554'394	-	65'791	78'073	-	6'862
Serious Bacterial Infections	703'143	-	-	-	-		-	703'143	-	-
Advancing Antibiotic R&D	2'801'504	47'473	32'255	14'961	2'543'915		44'753	104'746	-	13'401
International network expenditure	1'394'813	345'350	142'597	-	828'207	160	-	65'635	6'224	6'641
Fundraising & General and Administration	2'642'344	487'580	231'243	58'696	1'624'293	87'707	34'323	61'833	13'386	43'283
Financial expenses[2]	285'652	-	-	-	285'652	-	-	-	-	-
Total Opex	**24'000'286**	**6'535'470**	**1'000'000**	**467'118**	**13'947'162**	**447'110**	**144'868**	**1'231'757**	**141'476**	**85'324**

[1] *Other includes - South African Medical Research Council, The Leo Model Foundation, and the Grand Duchy of Luxembourg.*
[2] *Exchange loss – to be compensated in future years against any interest earned and exchange gains.*

2019 Funding per project

	TOTAL EXPENDITURE	UK DFID[1] (Unrestricted)	UK DHSC[2] (Unrestricted)	THE NETHERLANDS VWS (Unrestricted)	GERMANY BMG[3] (Restricted)	GERMANY BMBF (Restricted)	BILL & MELINDA GATES FOUNDATION[4] (Restricted)	SWITZERLAND[5] FOPH (Restricted)	SOUTH AFRICAN MEDICAL RESEARCH COUNCIL[6] (Restricted)	LEO MODEL FOUNDATION[7] (Unrestricted)	WELCOME TRUST[8] (Restricted)	PRINCIPALITY OF MONACO (Restricted)
Research & development coordination and supervision	4'250'544	193'494	69'384	28'198	382'786	3'346'826	-	49'598	215	5'672	165'446	8'924
International network expenditure	1'049'697	41'287	13'314	3'712	2'565	953'871	-	-	-	9'071	25'877	-
Neonatal Sepsis	2'801'705	-	33'191	-	84'076	1'595'168	831'050	-	58'687	326	117'289	81'918
Paediatrics	640'190	-	73'365	-	-	542'879	5'108	-	1'623	-	14'297	2'919
Antimicrobial Memory Recovery & Exploratory	1'236'462	-	-	-	-	880'013	-	124'114	36'088	-	196'247	-
Sexually Transmitted Infections	6'510'041	88'499	1'782'759	177'949	140'811	4'122'908	-	97'276	93'179		6'660	-
Fundraising & General and Administration	2'386'869	50'770	82'334	290'142	27'358	1'638'558	40'281	138'562	13'788	29'759	69'078	6'239
Financial expenses[2]	42'919	-	-	-	-	42'919	-	-	-	-	-	-
Total	**18'918'427**	**374'050**	**2'054'347**	**500'000**	**637'597**	**13'123'142**	**876'438**	**409'551**	**203'581**	**44'828**	**594'894**	**100'000**

[1] DNDI contract (DFID funding.)
[2] DHSC includes funding from the National Institue of Health Research (EUR 185'939). Includes EUR 36'394 of DNDI DHSC conract funding.
[3] Includes EUR 26'109 of DNDI BMG contract funding.
[4] Contract transferred from DNDi to GARP 1November 2019.
[5] Includes EUR 63'030 of DNDI FOPH contract funding.
[6] Includes EUR 39'778 of DNDI South African MRC contract funding.
[7] Leo Model Foundation contract with DNDI
[8] Wellcome Trust contract with DNDI
[9] Exchange loss - to be compensated in future years against any interest earned and exchange rate gains.

6. EXPENDITURE

Social mission expenditure encompasses expenses that support GARDP's mission to develop new treatments for drug-resistant infections. This includes work carried out and managed by the research & development, policy & advocacy, communications, and business development/access teams as well as our global network undertaking these activities. GARDP's non-social mission expenditure comprises our fundraising, IT, finance and human resources activities.

2020	SOCIAL MISSION		NON-SOCIAL MISSION		TOTAL
	OPERATIONAL EXPENDITURE	INTERNATIONAL NETWORK EXPENDITURE	FUNDRAISING	GENERAL AND ADMIN	
PARTNERS					
Purchase, logistics and equipment	29'361	56	-	-	29'416
Discovery, pre-clinical, training	817'668	-	-	-	817'668
Clinical & post-clinical	3'322'487	-	-	-	3'322'487
Product manufacturing & CMC	9'292'662	-	-	-	9'292'662
Personnel costs	4'895'231	984'221	551'363	1'102'010	7'532'826
Consultants	1'046'509	102'736	47'930	121'108	1'318'283
Travel expenses	78'099	9'277	9'306	-	96'683
Office costs, comms, admin and IT	195'458	298'523	3'484	722'580	1'220'046
Depreciation	-	-	-	84'563	84'563
Exceptional expenditure	-	-	-	-	-
TOTAL	**19'677'476**	**1'394'813**	**612'083**	**2'030'261**	**23'714'634**

2019	SOCIAL MISSION		NON-SOCIAL MISSION		TOTAL
	OPERATIONAL EXPENDITURE	INTERNATIONAL NETWORK EXPENDITURE	FUNDRAISING	GENERAL AND ADMIN	
PARTNERS					
Purchase, logistics and equipment	24'583	-	-	-	24'583
Discovery, pre-clinical, training	522'276	-	-	-	522'276
Clinical & post-clinical	4'764'024	-	-	-	4'764'024
Product manufacturing & CMC	3'217'825	-	-	-	3'217'825
Personnel costs	4'851'156	582'329	380'131	925'374	6'738'990
Consultants	968'467	60'857	-	227'867	1'307'191
Travel expenses	582'152	62'679	54'475	3'778	703'084
Office costs, comms, admin and IT	508'459	343'832	24'762	570'105	1'447'158
Depreciation	-	-	-	30'378	30'378
Exceptional Expenditure	-	-	-	120'000	120'000
TOTAL	**15'438'942**	**1'049'697**	**459'368**	**1'927'502**	**18'875'508**

Total operational expenditure has increased by 27%. The growth of operational expenses reflects the increased activity within the Serious Bacterial Infections programme and the strengthening of the R&D structure with the consolidation of the medical and pharmacovigilance functions and reinforcement of the clinical team throughout the year and across programmes.

7. INDEMNITIES & REMUNERATIONS GIVEN TO BOARD MEMBERS AND DIRECTORS

BOARD COMPENSATION

All members of the Board of Directors are appointed on a voluntary basis. Board of Directors members did not receive any remuneration for their mandate in 2020, nor did they in previous years.

GARDP DIRECTORS COMPENSATION

The GARDP Directors salaries (including benefits) in 2020 amounted to a total of CHF 1,556,114 / EUR 1,434,690 (7.8FTE). In 2019, this amount totalled CHF 1,090,897 / EUR 977,989 (5 FTE).

8. ASSETS PLEDGED, BANK GUARANTEE DEPOSITS AND CREDIT LINES

ASSETS PLEDGED

On 16 October 2018, the GARDP Foundation entered into a "master agreement for derivatives trading and forward transactions" and a pledge agreement with UBS Switzerland AG. The purpose is to allow GARDP to enter into Foreign Exchange Forward and Swap Contracts. There is no other pledge with any other third party.

CREDIT LINE

GARDP agreed a CHF500,000 credit line with a Swiss Bank under the Swiss Government backed credit liquidity scheme. GARDP has not needed to use the credit line.

9. COLLABORATIVE FUNDING AND IN-KIND CONTRIBUTIONS

COLLABORATIVE FUNDING

There was no collaborative funding in 2020. In 2019 collaborative funding totalled EUR 127,441.

IN-KIND CONTRIBUTIONS

In collaboration with its R&D partners and vendors, GARDP secured in-kind contributions from R&D partners to support its R&D programmes. These in-kind contributions were directly given to our partners and vendors for GARDP R&D-related activities and were as follows in 2020:

	STAFF NON SCIENTIFIC	STAFF SCIENTIFIC	OFFICE, FURNITURE, ADMIN & TRAVEL	R&D SERVICES	2020 TOTAL EUR	2019 TOTAL EUR
STI	-	-	-	-	-	10'885
AMR screening	-	21'444	7'395	15'010	43'850	91'318
Neonatal sepsis	4'801	410	-	-	5'211	11'187
TOTAL	**4'801**	**21'854**	**7'395**	**15'010**	**49'061**	**113'390**

Contributors: Daiichi Sankyo - Japan, Shionogi Co. Ltd - Japan, Eisai Co. Ltd - Japan & Takeda Pharmaceutical - Japan

For the policy on in-kind contributions, see Section 1.2: Significant accounting policies, N) In-kind contributions.

10. FINANCIAL INSTRUMENTS AND HEDGING ACTIVITIES

As of 31 December 2020 there were no forward contracts in place as the near-term requirement for each currency was covered. Similarly, there were no forward contracts in place as at 31 December 2019.

11. SWISS FRANC EQUIVALENT OF KEY FIGURES

GARDP maintains its accounting records in EUR. The key figures below have been translated into CHF for information purposes only, using a closing rate of CHF/EUR 0.9278 (2019 0.9113).

EXPRESSED (IN CHF)	2020	2019
Total assets	16'758'382	17'328'256
Capital of the organization	56'229	48'584
Total income	25'876'694	20'766'501
Total social mission expenditure	22'712'103	18'093'536
Total non-social mission expenditure	2'847'967	2'619'191

12. AUDIT FEES

Audit services include statutory audits, project audits, and donors' audits. In 2020, Deloitte, GARDP's Statutory Auditor, provided limited tax services in respect of VAT advice. In CHF, 2020 GARDP audit fees remained stable but decreased marginally compared to 2019 in Euros. Following a competitive audit tender, the GARDP Board again appointed Deloitte to complete a full scope audit in 2020 as part of our commitment to transparency even though the GARDP Foundation is not yet subject to a full scope audit in accordance with Swiss Law.

EXPRESSED (IN EUR)	2020	2019
Audit services	**30'593**	**31'398**
Other services	**-**	**12'952**
Total services	**30'593**	**44'350**

13. MATERIAL CONTRACTS

DND*i* COLLABORATION AND TRANSFER AGREEMENTS

Effective 1 January 2019, GARDP entered into a three-year collaboration agreement with DND*i*. Under this collaboration agreement, GARDP and DND*i* agreed to foster a strategic collaboration, sharing specialized R&D expertise and capacity, policy advocacy expertise, and some infrastructure and support services to drive efficiencies. In-country implementation of GARDP's programmes are supported by DND*i*'s international network and a joint DND*i* GARDP office in Southern Africa.

Effective 1 January 2019, GARDP also entered into a transfer agreement with DND*i*. Under this transfer agreement, all assets and employees were transferred to the new GARDP Foundation on 1 April 2019. The first tranche of R&D programme contracts were transferred on 1 January 2019 and the remaining transferred by 31 October 2019.

As a result of the above agreements, GARDP funded DND*i* in 2019 for the collaborative activities related to GARDP and for the costs incurred by DND*i* in connection with the R&D programmes until their completed transfer to GARDP in 2019. In 2020 the expenses related to the collaboration agreement paid by DND*i* on behalf of GARDP were as follows:

DND*i* EXPENDITURE REIMBURSEMENT	2020	2019
R&D expenditure paid by DND*i* (Transition costs in 2019)	-	5 067 000
Collaboration agreement expenses	3'265'799	2 489 461
Total DND*i* expenses reimbursement	**3'265'799**	**7 556 461**
Total GARDP expenditures	**23'714'634**	**18 875 5085**
Expenses as % of total expenditures	**13.8%**	**40.0%**

As at December 31, 2020, DND*i* and GARDP have two common Board members, Marie-Paule Kieny and Frédéric Vallat and four common Audit Committee members, Marie-Paule Kieny, Frédéric Vallat, Olivier Dunant and Barbara Kessler. DND*i* and GARDP are not related parties within the meaning of Swiss GAAP FER 15; neither DND*i* nor GARDP is directly or indirectly owned or controlled by the other organization, or by any other natural or legal person. All members of the GARDP Board and Audit Committee are appointed by the GARDP Board; they do not receive any remuneration for their mandates neither from DND*i* nor GARDP.

ENTASIS COLLABORATION AGREEMENT

Since 30 September 2019, GARDP and Entasis are partnering to complete late-stage development of zoliflodacin, with GARDP fully-funding and sponsoring the global phase 3 trial. Under the collaboration agreement, GARDP is responsible for the phase 3 trial and pharmaceutical development activities for zoliflodacin to support regulatory approval and market access and availability. GARDP has commercial rights to zoliflodacin in up to 168 low- and select middle-income countries, while Entasis retains commercial rights in the rest of the world. The phase 3 trial initiation marks an important milestone for this industry and not for profit partnership in jointly developing a novel antibiotic and building a strategic plan for successful market access within the countries that have high rates of gonorrhoea and for patients who need it most.

VENATORX COLLABORATION & LICENCE AGREEMENT

On 20 March 2020, GARDP entered into a collaboration and licence agreement with Venatorx Pharmaceuticals, a private US pharmaceutical company focused on the discovery and development of novel anti-infectives to treat multidrug-resistant bacterial and hard-to-treat viral infections. Under the collaboration, GARDP and Venatorx will accelerate the development of, and access to, cefepime-taniborbactam (formerly cefepime/VNRX-5133). Cefepime-taniborbactam is an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA).

GARDP is collaborating with Venatorx to complete the development of cefepime-taniborbactam, which includes a phase 3 complicated urinary tract infection (cUTI) trial, which is already in progress; additional clinical trials in adults with multidrug-resistant infections; and clinical development activities and trials to enable cefepime-taniborbactam to be used for children, including newborns with serious bacterial infections. This collaboration & licence agreement is the first collaboration under GARDP's new Serious Bacterial Infections programme. GARDP and Venatorx have committed to provide affordable access of cefepime-taniborbactam in patients globally, including for underserved populations and geographies, and to ensure its preservation through adapted and implementable stewardship measures.



14. SUBSEQUENT EVENTS

OTHER INTERNATIONAL ORGANIZATION STATUS

As outlined in note 1.1.B “Income Tax”, on 10 March 2021 the Swiss Federal Council signed an agreement with GARDP granting GARDP privileged status in Switzerland. By signing the agreement, the Federal Council recognizes the major role played at the international level by GARDP in the fight against antibiotic resistance.

The signing of the agreement represents a significant recognition of GARDP’s mission to develop new treatments for the drug-resistant infections that pose among the greatest threats to health.

No other subsequent events have taken place in 2021.

GOVERNANCE

The GARDP Foundation operates with the following core structures:

BOARD OF DIRECTORS

GARDP's Board of Directors is the ultimate policy and decision-making authority and includes leading international figures in global health. The Board determines GARDP's strategic goals and ensures the management works efficiently to meet these goals.

The Board of Directors is comprised of up to fifteen members and meets at least twice a year. All board members are experts in their respective fields. They have been chosen for their commitment to the public interest and technical credibility to oversee executive activity, integrity, and skill in ensuring adherence to GARDP's vision and mission. The Chair of the Scientific Advisory Committee, Chair of the Donor Partnership Advisory Committee and the Executive Director are permanent invitees.

In 2020, Dr Hiroki Nakatani from Japan's Global Research Institute at Keio University joined the Board as its newest member and Professor Hanan H. Balkhy, Assistant Director-General for Antimicrobial Resistance at the World Health Organization, joined the Board as Observer. With a broader knowledge base and depth of experience, an expanded board will ensure good governance of new and ongoing R&D and access programmes, the strategy to deliver on the business plan, and ensure this strategy is matched with the required resources. Procedures for the appointment of Board members are guided by GARDP's statutes and by-laws as approved by the Swiss Supervisory Board for Foundations.

BOARD MEMBERS

Ramanan LAXMINARAYAN
Chair, Center for Disease Dynamics, Economics and Policy, USA

Marie-Paule KIENY
Vice-chair, Institut national de la santé et de la recherche médicale, INSERM, France

Frédéric VALLAT
Treasurer, Ville de Genève, Switzerland

Glenda GRAY
South African Medical Research Council, South Africa

Hiroki NAKATANI (new member)
Global Research Institute, Keio University, Japan

Mercedes TATAY
Médecins Sans Frontières

Veronika VON MESSLING
Federal Ministry of Education and Research (BMBF), Germany

OBSERVERS

Hanan H. BALKHY
World Health Organization, Switzerland

Prabhavathi FERNANDES
Chair of GARDP Scientific Advisory Committee

Ambassador Nora KRONIG ROMERO
Chair of GARDP Donor Partnership Advisory Committee

Bernard PÉCOUL
Drugs for Neglected Diseases initiative, Switzerland

Manica BALASEGARAM
Ex officio, GARDP

THE BOARD HAS CREATED 3 SUB-COMMITTEES AND 2 ADVISORY COMMITTEES:

- Audit Committee
- Nominations, Remuneration & Safeguarding Committee
- Strategic Partnerships Committee
- Scientific Advisory Committee
- Donor Partnership Advisory Committee

AUDIT COMMITTEE

This Committee is responsible for the selection and oversight of the work of the auditors, recommending financial policies, reviewing financial statement and supervising GARDP investments. Independent and external to GARDP's operations and management, this committee undertakes controls and monitors compliance to GARDP's statutory provisions and legal standards. The Audit Committee reports to the Board any irregularities noted during audits. The Audit Committee is held twice a year, generally ahead of the Board.

MEMBERS

Marie-Paule KIENY
Vice-chair, Institut national de la santé et de la recherche médicale, INSERM, France

Frédéric VALLAT
Treasurer, Ville de Genève, Switzerland

Olivier DUNANT
Attorney at law, Partner Eversheds Sutherland, Geneva, Switzerland

Barbara KESSLER
Board member University Hospital Basel, former Head of Tax Novartis, Basel, Switzerland

NOMINATIONS, REMUNERATION & SAFEGUARDING COMMITTEE

This Committee is responsible for regularly reviewing the structure, size and composition of the Board, and making recommendations to the Board with regard to such matters and, in particular, the appointment of members to Board committees. It ensures that the Board and its committees have the appropriate balance of expertise, experience, independence and knowledge of GARDP to enable them to discharge their respective duties and responsibilities effectively.

MEMBERS

Ramanan LAXMINARAYAN
Chair, Center for Disease Dynamics, Economics and Policy, USA

Marie-Paule KIENY
Vice-chair, Institut national de la santé et de la recherche médicale, INSERM, France

Frédéric VALLAT
Treasurer, Ville de Genève, Switzerland

Hiroki NAKATANI
Global Research Institute, Keio University, Japan

STRATEGIC PARTNERSHIPS COMMITTEE

This Committee ensures that the strategic partnerships sought by GARDP with the private sector (mainly SME's and manufacturers) in building its product portfolio are done in accordance with its vision, mission and objectives. The Committee ensures that partnerships are crafted to ensure GARDP's independence, and that they contain all the necessary provisions to protect the organization, its public health mission and its investments, while respecting all relevant policies and procedures of GARDP.

MEMBERS

Glenda GRAY
Chair, South African Medical Research Council, South Africa

Veronika VON MESSLING
Federal Ministry of Education and Research (BMBF), Germany

Ramanan LAXMINARAYAN
Center for Disease Dynamics, Economics and Policy, USA

Frédéric VALLAT
Treasurer, Ville de Genève, Switzerland

SCIENTIFIC ADVISORY COMMITTEE (SAC)

The SAC is composed of prominent scientists with expertise in various scientific disciplines relating to drug discovery and development, and/or antimicrobial resistance and patients. The SAC operates independently of the Board and the Management Team. Its members advise GARDP's Board of Directors in order to carry out GARDP's scientific objectives, assess its scientific strategy and projects and provide guidance and medical and scientific expertise to GARDP's programmes.

MEMBERS

Prabhavathi FERNANDES
Chair, USA

Karl-Heinz ALTMANN
Swiss Federal Institute of Technology, Switzerland

Marc BONTEN
University Medical Centre Utrecht, The Netherlands

Anthony COATES
St George's University, UK

Mark J GOLDBERGER
formerly AbbVie, USA

William HOPE
University of Liverpool, UK

Kazuki HOSHINO
Daiichi Sankyo, Japan (up to 30 April 2020)

Rudo MATHIVHA
Chris Hani Baragwanath Hospital, South Africa

Marc MENDELSON
University of Cape Town, South Africa

Malcolm PAGE
formerly Roche, Switzerland

Andreas RUMMELT
InterPharmaLink AG, Switzerland

Kamini WALIA
Indian Council of Medical Research, India

Nicholas WHITE
Mahidol University, Thailand

OBSERVERS

Laurent FRAISSE
Drugs for Neglected Diseases initiative

Sarah PAULIN
World Health Organization, Switzerland

THE DONOR PARTNERSHIP ADVISORY COMMITTEE (DPAC)

The DPAC ensures key funding partners are represented as stakeholders and partners in GARDP, allowing them to bring their insights to the Board. Importantly, it provides advice and member state perspectives that assist the Board and the organization more broadly in fulfilling its mission. The Committee reviews the success of previous and ongoing donor investments made to GARDP and provides advice to the Board on how further funding can deliver the highest possible impact. It also provides advice on how GARDP can widen and better manage its partnerships with member states and other important global health funders. The Chair of the Committee represents the Committee at the Board meetings and ensures that key decisions of the Board are brought back to the full Committee.

DONOR

Ambassador Nora KRONIG ROMERO
Chair, Federal Office of Public Health, Switzerland

Niresh BHAGWANDIN
South African Medical Research Council, South Africa

Jasper CLAESSEN
Ministry of Health, The Netherlands

Louise NORTON-SMITH
Department of Health and Social Care, UK

Dagmar REITENBACH
Federal Ministry of Health, Germany

Yasuyuki SAHARA
Ministry of Health, Labor and Welfare, Japan

GARDP LEADERSHIP & PROGRAMMES

GARDP's leadership team and staff work to deliver on our vision by supporting the R&D ecosystem while developing and securing sustainable access to new treatments.

GARDP has a flexible R&D operating model that enables cross-functional project leadership integrating technical disciplines from across GARDP and our partners. At the core of the model is a collaborative project team focussing on the development of a drug and delivery of an antibiotic treatment. The collaborative project teams lead by GARDP project leaders follow development plans underpinned by target treatment/product profiles with progress reviewed via GARDP R&D governance and a GARDP Board-appointed Scientific Advisory Committee.

GARDP DIRECTORS

Manica BALASEGARAM
Executive Director

Seamus O'BRIEN
Research & Development Director

Vincent CONSTANTIN
General Counsel

Pierre-Yves DELHEZ
Internal Operations Director

Jennifer KATZ
External Affairs Director

Jean-Pierre PACCAUD
Business Development and Corporate Strategy Director

Laura PIDDOCK
Scientific Affairs Director

Subasree SRINIVASAN
Consultant Medical Director

PROGRAMME LEADS

Emilie ALIROL
Sexually Transmitted Infections Project Leader (up to 30 September)

Seamus O'BRIEN
Sexually Transmitted Infections Interim Project Leader (as of 1 October)

Sally ELLIS
Children's Antibiotics Project Leader

François FRANCESCHI
Serious Bacterial Infections and Asset Evaluation and Development Project Leader

Julie MIRALVES
R&D Portfolio and Planning Leader

REPORT OF THE STATUTORY AUDITOR

Deloitte.

Deloitte SA
Rue du Pré-de-la-Bichette 1
1202 Geneva
Switzerland

Phone: +41 (0)58 279 8000
Fax: +41 (0)58 279 8800
www.deloitte.ch

Report of the Auditor

To the Board of the Foundation of
Global Antibiotic Research & Development Partnership (GARDP) Foundation, Geneva

As statutory auditor, we have audited the accompanying combined financial statements of Global Antibiotic Research & Development Partnership (GARDP) foundation which comprise the combined balance sheet as at 31 December 2020, the combined statement of operations, the combined funds flow statement, the combined statement of changes in capital and notes to the combined financial statements, presented on pages on pages 17 to 38, for the year then ended.

Board of the Foundation's Responsibility
The Board of the Foundation is responsible for the preparation of these combined financial statements in accordance with Swiss GAAP FER, the requirements of Swiss law and the charter of the foundation. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of combined financial statements that are free from material misstatement, whether due to fraud or error. The Board of the Foundation is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility
Our responsibility is to express an opinion on these combined financial statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the combined financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the combined financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the combined financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control system relevant to the entity's preparation of the combined financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control system. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the combined financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Deloitte.

Global Antibiotic Research &
Development Partnership (GARDP), Geneva
Report of the statutory auditor
For the year ended 31 December 2020

Opinion
In our opinion, the combined financial statements for the year ended 31 December 2020 give a true and fair view of the financial position, the results of operations and the cash flows in accordance with Swiss GAAP FER and comply with Swiss law and the charter of the foundation.

Report on Other Legal Requirements

We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence (article 83b Civil Code (CC) in connection with article 728 Code of Obligations (CO)) and that there are no circumstances incompatible with our independence.

In accordance with article 728a para. 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of combined financial statements according to the instructions of the Board of the Foundation.

We recommend that the combined financial statements submitted to you be approved.

Deloitte SA

Fabien Bryois
Licensed Audit Expert
Auditor in Charge

Sophie Durand
Licensed Audit Expert

Geneva, 06 July 2021
FBR/SDU/mab

Enclosures
- Financial statements (combined balance sheet, combined statement of operations, combined funds flow statement, combined changes in capital and notes)

A WORD OF THANKS

GARDP aims to deliver 5 new treatments for drug-resistant infections by 2025 that pose the greatest threat to health. GARDP is extremely grateful for the commitment of all its funders in helping us address the silent pandemic of drug-resistant infections. Thank you for your loyal support

CONTACT

GARDP HEADQUARTERS

Chemin Camille-Vidart 15 – 1202 Geneva Switzerland
Tel: +41 22 906 9230 – Fax: +41 22 906 9231
contact@gardp.org – www.gardp.org

DND*i* GARDP SOUTHERN AFRICA NPC

c/o MSF, Deneb House,
cnr Main and Browning roads,
Observatory, Cape Town, 7935

Credits

Copyright : The GARDP Foundation, 2021
Design : ©Enigma

twitter.com/gardp_amr
linkedin.com/company/gardp


GARD P